TrialUrologic oncology2014

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).

Andrew J Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.